Hypertension is a serious global public health problem. It accounts for 10% of all deaths in India and is the leading non-communicable disease. Recent studies have shown that the prevalence of hypertension is 25% in urban and 10% in rural people in India. It exerts a substantial public health burden on cardiovascular health status and health care systems in India. Antihypertensive treatment effectively reduces hypertensionrelated morbidity and mortality. The cost of medications has always been a barrier to effective treatment. The increasing prevalence of hypertension requires use of cost effective treatment for the effective management of the disease. The present study assesses the cost-effectiveness of antihypertensive drugs in patients with hypertension from Mumbai, India. A cross-sectional study was conducted to assess the costeffectiveness of antihypertensive drugs. Face-to-face interviews were conducted by using a validated questionnaire in a total of 136 (66 males, 70 females) patients with hypertension from F-North Ward, Mumbai, India. Cost-effectiveness was determined on the basis of cost of antihypertensive drug/s, efficacy, adverse drug reactions, safety of administration, frequency of administration, and bioavailability. Atenolol was found to be the most cost-effective (INR 5.5/unit of effectiveness), followed by the amlodipine + losartan combination (INR 5.6), amlodipine (INR 6.3), captopril (INR 6.9), amlodipine + lisinopril (INR 9.6), losartan (INR 14.5) and lisinopril (INR 17.2) in the present study. Thirty-eight (28%) patients received combination therapy. Lisinopril prescribed to16 (11.8%) patients was the least cost-effective drug (INR: 17.2/unit of effectiveness). Prescriptions of cost-effective antihypertensive drugs (73.5%) were more common than less cost-effective antihypertensive drugs (26.5%) in hypertensive patients from Mumbai, India. Most of the patients (72%) were prescribed monotherapy in the treatment of hypertension.
INTRODUCTION
Hypertension is ranked as the third most important risk factor for attributable burden of disease in south Asia (2010) 1 . It exerts a substantial public health burden on cardiovascular health status and healthcare systems in India 2, 3 . HTN is directly responsible for 57% of all stroke deaths and 24% of all coronary heart disease (CHD) deaths in India 4 . This fact is significant as hypertension is a controllable disease and population-wide reduction in the blood pressure by 2mmHg can prevent 151,000 strokes and 153,000 coronary heart disease deaths in India 5 . The WHO rates HTN as one of the most important causes of premature death worldwide 6 . The Global and Regional Burden of Disease and Risk Factors study (2001) , in a systematic analysis of population health data for attributable deaths and attributable disease burden, has ranked HTN in south Asia as second only to child underweight for age 7 . Hypertension accounts for 10% of worldwide healthcare expenditure underlining the considerable economic implications to resource constrained health systems 8 . Apart from health implications it has huge societal, developmental and economic costs. There is also noteworthy income loss to families affected by hypertension not only due to illness but also due to care giving and premature death 8 . In 2004, the annual income loss from NCDs among working adults in India was INR 251 billion (about US$ 50 billion) and that due to hypertension alone amounted to INR 43 billion 8 . It has been estimated that less than 20% of hypertensive patients have adequate control of blood pressure 9 . Even though randomized clinical trials have determined the efficacy of antihypertensive treatment, the effective control of hypertension depends on case detection and adequate management by health professionals, followed by the long-term adhesion of patients to the treatment 10 .Antihypertensive drug treatment often has elevated costs 11 , a limitation that has not always been taken into account in clinical practice 12 .Cost-effectiveness analysis is seldom available, particularly with regard to the individualization of costs.
Rationale
The developments of the last 50 years in the pharmaceutical armamentarium against hypertension have brought significant reductions in cardiovascular morbidity and mortality among hypertensive patients 13, 14 . Nevertheless, the current (and future) obligation of health care systems to operate under severe financial constraints necessitates the use of not only clinical effectiveness but also economical efficiency data associated with each treatment option. In this light, a large number of economic evaluations comparing the incremental costs and effects between different classes of drugs 15, 16 , or among newer and older agents of the same therapeutic class 17 , have been published. Almost all of the aforementioned studies have concluded that hypertension treatment represents an intervention that is associated with extremely favorable cost-effectiveness ratios 18 . In light of the above, and in order to contribute to this discussion; the purpose of the present study was to assess the cost-effectiveness of antihypertensive drugs in patients with hypertension from Mumbai, India.
Methods

Study design and participants
A cross sectional study was designed based on validated survey questionnaire. It was conducted in F-North ward of Mumbai, Maharashtra, India. Ethical approval was obtained from V.V. Hospital Independent Ethics Committee, Thane, India. Information about apartments and family members was acquired from the office of F-North ward, Mumbai Municipal Corporation. From their database, 1000 apartments having subjects within the age group of 30 -75 were randomly selected. These apartments were visited by trained pharmacy students and a total of 200 subjects satisfying the inclusion criteria were identified from which 166 agreed to participate. The Inclusion criteria were age of 18 -65 years, diagnosis of primary hypertension, a consultation and a blood pressure report from a physician within the period of 30 days prior to the interview date and written informed consent to participation in the study. Exclusion criteria were subjects with a recent cardiovascular episode (<1 year), known or suspected secondary hypertension, serious illness or pregnancy.
Study instrument
A survey questionnaire was designed in English after discussion with experts and a literature review of similar studies. The questionnaire was translated into Marathi and Hindi by experienced translator and back translated to English to ensure the content uniformity by another experienced translator. A pilot study was conducted in a sub sample of 30 subjects to ensure that the questionnaire would be appropriate, and understandable among the prospective respondents. The pilot testing allowed wording modifications in questions and also gave estimate of the average time required for interview and filling of the questionnaire. This population was not part of the final study.
Collection of data
Each selected apartment was visited by trained pharmacy student to collect the data. The purpose of the research was explained to the participant. Anonymity and confidentiality were guaranteed and maintained. The researchers complied with the international ethical guidelines for research. The information collected from each participant included the gender, age, occupation, marital status, religion, education, monthly family income per family member, waist / hip ratio, date since hypertensive, Systolic and diastolic blood pressure report from physician (in last 30 days), name, formulation, strength, price of antihypertensive/s medication, side effects if any and health insurance. The three reading of Supine blood pressure were taken by trained pharmacy student using a digital sphygmomanometer and the mean of these readings was considered for final calculation. Waist and hip circumferences (cm) were measured in duplicate with an anthropometric tape while the subjects were wearing light clothing. Waist circumference was measured at the minimum circumference between the iliac crest and the rib cage. Hip circumference was measured at the maximum protuberance of the buttocks, and the WHR was calculated. Data was recorded into predesigned case report form (CRF) by interviewers.
Data entry and analysis
Collected data from individual CRF was entered into Microsoft excel and was verified by the authors other than interviewers. The data were analyzed by Microsoft excel for finding out relevant statistics. Qualitative variables were analyzed statistically, presented as frequencies and percentages.
Cost-effectiveness calculations
Cost effectiveness calculations were done by following method.
• Bioavailability: For every treatment bioavailability was determined from the standard pharmacology text book 19 .
• This was done and compared for each antihypertensive treatment option presently prescribed for the respondents in this study.
• Sensitivity analysis was performed to test whether the decisions change when specific variable (e.g. cost, effectiveness) were altered within reasonable range (10-25%) in favor of less cost-effective option in the management of hypertension. As shown in Table 3 Sensitivity analysis done by assuming 25% increase in the cost and 25% decrease in the cost, indicated that the decision remains valid, confirming Atenolol was most cost effective treatment for study participants. which showed that Atenolol was most costeffective for the treatment of essential hypertension in comparison to conventional anti-hypertensive treatment. This study was able to describe the cost of the treatment and control of hypertension for patients taking blood pressure-lowering drugs. The selection of a population-based sample has the advantage of including a representative sample of the entire population and allows the costeffectiveness of treatment based on drugs actually in use to be assessed, thereby differing from indirect estimates based upon data from production and sales of drugs, medical records or participants in randomized clinical trials 10 . Economic evaluation cannot provide a solution to all health care policy issues. However it does represent a significant input to the decision making process 24 , the latter including a series of health-related and societal values that should be taken into account in the context of resource allocation. Hypertension given its chronicity and associated morbidity and mortality, constitutes a significant disease burden to the society, both in terms of the health-related repercussions as well as financial costs incurred due to morbidity and the cumulative cost of drug therapy 25 . As neither the symptoms of hypertension nor the beneficial effects of lowering blood pressure are readily apparent to patients, it is important to administer drugs that are cost-effective and have minimal adverse effects. This is particularly important in a developing country like India 25 , where, the accretive cost of long-term therapy is often a significant deterrent to patient compliance. The results of this study contribute towards decision making involved in formulary management and by clinicians treating patients with hypertension. 
RESULTS
CONCLUSION
Prescriptions of cost-effective antihypertensive drugs (73.5%) were more common than less costeffective antihypertensive drugs (26.5%) in hypertensive patients from Mumbai, India. Most of the patients (72%) were prescribed monotherapy in the treatment of hypertension.
